Should I buy or sell Aldeyra Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALDX shares. View ALDX analyst ratings or view top-rated stocks .

What is Aldeyra Therapeutics' stock price target for 2024?

3 brokerages have issued 12-month price objectives for Aldeyra Therapeutics' stock. Their ALDX share price targets range from $8.00 to $15.00. On average, they expect the company's stock price to reach $12.33 in the next twelve months. This suggests a possible upside of 295.3% from the stock's current price. View analysts price targets for ALDX or view top-rated stocks among Wall Street analysts .

How have ALDX shares performed in 2023?

Aldeyra Therapeutics' stock was trading at $6.96 at the beginning of 2023. Since then, ALDX shares have decreased by 55.2% and is now trading at $3.12. View the best growth stocks for 2023 here .

Are investors shorting Aldeyra Therapeutics?

Aldeyra Therapeutics saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 3,160,000 shares, a decline of 5.7% from the October 31st total of 3,350,000 shares. Based on an average daily volume of 2,520,000 shares, the short-interest ratio is presently 1.3 days. Currently, 5.6% of the shares of the stock are sold short. View Aldeyra Therapeutics' Short Interest .

When is Aldeyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, December 7th 2023. View our ALDX earnings forecast .

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) announced its quarterly earnings data on Wednesday, October, 27th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.01. During the same period in the prior year, the business posted ($0.23) earnings per share.

What ETF holds Aldeyra Therapeutics' stock ?

Invesco Dorsey Wright Healthcare Momentum ETF holds 172,465 shares of ALDX stock, representing 0.81% of its portfolio.

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA) , Matinas BioPharma (MTNB) , Sorrento Therapeutics (SRNE) , KushCo (KSHB) , Bionano Genomics (BNGO) , Gran Tierra Energy (GTE) , Zosano Pharma (ZSAN) , Novan (NOVN) , Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI) .

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Laurion Capital Management LP (1.92%), Eagle Asset Management Inc. (1.77%), Deutsche Bank AG (0.50%), Deutsche Bank AG (0.50%), Rafferty Asset Management LLC (0.46%) and Ameriprise Financial Inc. (0.34%). Insiders that own company stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc and Todd C Brady. View institutional ownership trends .

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Aldeyra Therapeutics Stock Price, News & Analysis (NASDAQ:ALDX)

$3.24

+0.12 (+3.85%)

(As of 12:45 PM ET)

Compare

Today's Range: $3.05
▼
$3.25
50-Day Range: $1.47
▼
$6.68
52-Week Range: $1.42
▼
$11.97

Volume: 338,557 shs
Average Volume: 1.35 million shs
Market Capitalization: $190.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.33

Aldeyra Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 295.3% Upside
$12.33 Price Target
Short Interest: Healthy
5.59% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.19
Based on 6 Articles This Week
Insider Trading: Selling Shares
$4.45 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.76) to ($1.08) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

540th out of 949 stocks

Pharmaceutical Preparations Industry

238th out of 421 stocks

3.3

Analyst's Opinion

Consensus Rating
Aldeyra Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.33, Aldeyra Therapeutics has a forecasted upside of 295.3% from its current price of $3.12.
Amount of Analyst Coverage
Aldeyra Therapeutics has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
5.59% of the float of Aldeyra Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Aldeyra Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aldeyra Therapeutics has recently decreased by 5.67%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aldeyra Therapeutics does not currently pay a dividend.
Dividend Growth
Aldeyra Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALDX.

1.8

News and Social Media Coverage

News Sentiment
Aldeyra Therapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Aldeyra Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 17 people have searched for ALDX on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aldeyra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,453,308.00 in company stock.
Percentage Held by Insiders
Only 7.30% of the stock of Aldeyra Therapeutics is held by insiders.
Percentage Held by Institutions
66.62% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Aldeyra Therapeutics are expected to decrease in the coming year, from ($0.76) to ($1.08) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aldeyra Therapeutics is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aldeyra Therapeutics is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aldeyra Therapeutics has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aldeyra Therapeutics Stock (NASDAQ:ALDX)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

ALDX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALDX Stock News Headlines

December 5, 2023 | finance.yahoo.com

Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings?

December 5, 2023 | americanbankingnews.com

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Significant Decrease in Short Interest

December 6, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

December 2, 2023 | americanbankingnews.com

Research Analysts Set Expectations for Aldeyra Therapeutics, Inc's FY2023 Earnings (NASDAQ:ALDX)

November 28, 2023 | bizjournals.com

Lexington biotech gets second FDA rejection this year

November 28, 2023 | msn.com

FDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional Study

November 27, 2023 | msn.com

FDA says more data needed to approve Aldeyra dry eye drug (update)

November 27, 2023 | finance.yahoo.com

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

December 6, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 1, 2023 | benzinga.com

What's Going On With Aldeyra Therapeutics Stock?

November 1, 2023 | investorplace.com

Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?

October 19, 2023 | benzinga.com

10% Owner of Aldeyra Therapeutics Makes $4.45M Sale

October 18, 2023 | msn.com

Oppenheimer Downgrades Aldeyra Therapeutics (ALDX)

October 18, 2023 | msn.com

Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More

October 17, 2023 | finance.yahoo.com

Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback

October 17, 2023 | proactiveinvestors.com

Aldeyra Therapeutics stock tanks on warning that FDA will reject new drug application

October 17, 2023 | markets.businessinsider.com

Citi Analyst Retains Buy Rating for Aldeyra Therapeutics Despite FDA Concerns and Revised Projections

October 16, 2023 | nasdaq.com

Aldeyra Therapeutics Falls After FDA Indicated Addl. Clinical Trial For Reproxalap For Dry Eye

October 16, 2023 | msn.com

Aldeyra says FDA may not approve dry eye drug, stock plunges 63%

October 16, 2023 | benzinga.com

Why Aldeyra Therapeutics (ALDX) Stock Is Getting Obliterated

September 29, 2023 | markets.businessinsider.com

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses to Contact the Firm

September 28, 2023 | stockhouse.com

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

September 28, 2023 | tmcnet.com

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)

September 26, 2023 | businesswire.com

Deadline Alert: ALDX Investor Alert: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Aldeyra Therapeutics, Inc. Class Action Lawsuit

September 25, 2023 | stockhouse.com

FRIDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

September 24, 2023 | prnewswire.com

ALDX FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX

September 18, 2023 | msn.com

Eyeing Returns: Aldeyra's Shift From Lab To Market

See More Headlines

Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/27/2021
Today: 12/06/2023
Next Earnings (Estimated): 12/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALDX
CUSIP: N/A
CIK: 1341235
Web: www.ampliphibio.com
Phone: 781-761-4904
Fax: 781-270-0630
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.33
High Stock Price Target: $15.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +295.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-62,030,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -33.77%
Return on Assets: -28.01%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 6.81
Quick Ratio: 6.81

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.58 per share
Price / Book: 1.21

Miscellaneous

Outstanding Shares: 58,820,000
Free Float: 54,528,000
Market Cap: $183.52 million
Optionable: Optionable
Beta: 1.40

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Todd C. Brady (Age 48)
M.D., Ph.D., Chief Executive Officer and Director
Joshua Reed (Age 47)
Chief Financial Officer
David McMullin (Age 45)
Chief Commercial Officer
James A. Gow (Age 53)
M.D., Senior Vice President of Clinical Development
Stephen G. Machatha (Age 43)
Ph.D., Senior Vice President, Technical Operation

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Aldeyra Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALDX shares.
View ALDX analyst ratings or view top-rated stocks.
What is Aldeyra Therapeutics' stock price target for 2024?: 3 brokerages have issued 12-month price objectives for Aldeyra Therapeutics' stock. Their ALDX share price targets range from $8.00 to $15.00. On average, they expect the company's stock price to reach $12.33 in the next twelve months. This suggests a possible upside of 295.3% from the stock's current price.
View analysts price targets for ALDX or view top-rated stocks among Wall Street analysts.
How have ALDX shares performed in 2023?: Aldeyra Therapeutics' stock was trading at $6.96 at the beginning of 2023. Since then, ALDX shares have decreased by 55.2% and is now trading at $3.12.
View the best growth stocks for 2023 here.
Are investors shorting Aldeyra Therapeutics?: Aldeyra Therapeutics saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 3,160,000 shares, a decline of 5.7% from the October 31st total of 3,350,000 shares. Based on an average daily volume of 2,520,000 shares, the short-interest ratio is presently 1.3 days. Currently, 5.6% of the shares of the stock are sold short.
View Aldeyra Therapeutics' Short Interest.
When is Aldeyra Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, December 7th 2023.
View our ALDX earnings forecast.
How were Aldeyra Therapeutics' earnings last quarter?: Aldeyra Therapeutics, Inc (NASDAQ:ALDX) announced its quarterly earnings data on Wednesday, October, 27th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.01. During the same period in the prior year, the business posted ($0.23) earnings per share.

What ETF holds Aldeyra Therapeutics' stock ?: Invesco Dorsey Wright Healthcare Momentum ETF holds 172,465 shares of ALDX stock, representing 0.81% of its portfolio.
What other stocks do shareholders of Aldeyra Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).
Who are Aldeyra Therapeutics' major shareholders?: Aldeyra Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Laurion Capital Management LP (1.92%), Eagle Asset Management Inc. (1.77%), Deutsche Bank AG (0.50%), Deutsche Bank AG (0.50%), Rafferty Asset Management LLC (0.46%) and Ameriprise Financial Inc. (0.34%). Insiders that own company stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc and Todd C Brady.
View institutional ownership trends.
How do I buy shares of Aldeyra Therapeutics?: Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ALDX) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial